MedTrace Logo

A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA

NCT07586735 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2026-07-06

No results posted yet for this study

Summary

The goal of this prospective, multicenter, single arm observational study is to evaluate the efficacy and safety of the BFCA regimen in ≥ 40 years old SAA patients undergoing haplo-HSCT.

Conditions

  • Severe Aplastic Anemia
  • Aplastic Anaemia
  • Hematopoietic Cell Transplant

Interventions

DRUG

BFCA conditiong regimen

busulfan 0.8 mg/kg/6h (days -8 to -7), fludarabine 30mg/m2/day (days -6 to -2), cyclophosphamide 25 mg/kg/day (days -5 to -2) and antithymocyte globulin(ATG) 2.5 mg/kg/day (days -5 to -2).

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-12-31
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07586735 on ClinicalTrials.gov